-
A Message from the Editor-in-Chief: End of An Era
A final goodbye It is with a heavy heart that I write this last piece for Perspectives in Primary Care. Current financial realities have necessitated... -
An Underrated Barrier to Healthcare: It's Not Just About Cost
“Thank you for calling our free clinic. How can I help you?” I have spent countless hours listening to the pleas of people in desperate need of... -
A Guide to Geriatric Psychiatry Referral for Health Care Professionals and Caregivers
Our aging global population has the potential to enrich our communities, strengthen intergenerational relationships, and help preserve our cultural...
Archive
As of June 30, 2025, Perspectives in Primary Care is no longer active.
Perspectives in Primary Care features writing from practitioners, activists, and community members representing organizations, practices, and institutions across the United States and around the world.
Reference
Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacy Perspective on Insurance Coverage and Medication Access
Glucagon-like peptide-1 receptor agonists, more commonly referred to as GLP-1s, have undoubtedly garnered much fanfare the past five years. This class of medications is prescribed for many indications including diabetes, weight loss, and to reduce the risk of heart attack and stroke in adults with heart disease. The first GLP-1, Byetta (exenatide), was approved by the Food and Drug Administration (FDA) in 2005 to treat diabetes mellitus Type 2. It was not until 2014 that the first GLP-1 was ...
